These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 33504013)

  • 1. Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy.
    Pugazhendhi A; Hubbell M; Jairam P; Ambati B
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33504013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation.
    Little K; Ma JH; Yang N; Chen M; Xu H
    EBioMedicine; 2018 Dec; 38():283-291. PubMed ID: 30473378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
    Andreoli CM; Miller JW
    Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
    Koo HC; Baek YY; Choi JS; Kim YM; Sung B; Kim MJ; Kim JG; You JC
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement System and Potential Therapeutics in Age-Related Macular Degeneration.
    Park YG; Park YS; Kim IB
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches.
    Ricci F; Bandello F; Navarra P; Staurenghi G; Stumpp M; Zarbin M
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model.
    Kim SY; Kambhampati SP; Bhutto IA; McLeod DS; Lutty GA; Kannan RM
    Exp Eye Res; 2021 Feb; 203():108391. PubMed ID: 33307075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct effects of complement and of NLRP3- and non-NLRP3 inflammasomes for choroidal neovascularization.
    Malsy J; Alvarado AC; Lamontagne JO; Strittmatter K; Marneros AG
    Elife; 2020 Dec; 9():. PubMed ID: 33305736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases.
    Yao PL; Peavey J; Malek G
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration.
    Marneros AG
    Cell Rep; 2013 Sep; 4(5):945-58. PubMed ID: 24012762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMD--the retinal disease with an unprecised etiopathogenesis: in search of effective therapeutics.
    Nowak JZ
    Acta Pol Pharm; 2014; 71(6):900-16. PubMed ID: 25745762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development.
    Hanout M; Ferraz D; Ansari M; Maqsood N; Kherani S; Sepah YJ; Rajagopalan N; Ibrahim M; Do DV; Nguyen QD
    Biomed Res Int; 2013; 2013():830837. PubMed ID: 24319688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM; Pruente C
    Prog Retin Eye Res; 2007 Jul; 26(4):437-51. PubMed ID: 17512238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
    Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
    Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
    Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH
    Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of gene therapy for treatment of age-related macular degeneration.
    Askou AL
    Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-A and the NLRP3 Inflammasome in Age-Related Macular Degeneration.
    Marneros AG
    Adv Exp Med Biol; 2016; 854():79-85. PubMed ID: 26427397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current therapeutic approaches in neovascular age-related macular degeneration.
    Nguyen DH; Luo J; Zhang K; Zhang M
    Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.